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ABSTRACT 
The recent application of pharmacogenetics to the kidney transplantation process has 
provided a new method for creating drug dosage regimes that are specific to each patient. These 
regimes are based on a patient’s genotype, which is usually obtained from a blood sample. The 
purpose of this study was to determine whether saliva samples could be used as a less invasive 
alternative to blood samples for examining genes of interest in transplant patients. To test this 
hypothesis, the amount and purity of DNA was measured from four saliva samples. Following 
this, the purified DNA was run with the human primer for the SNP RS7767396 to determine if it 
had potential for use in further testing.  The results from this work suggest that saliva samples 
produce an amount of DNA useful for further pharmacogenetic testing, though the resulting 
product contains more impurities than the DNA obtained from blood. These results imply that 
saliva samples could possibly be used as an alternative to blood samples in the future, making it 
more likely that patients would agree to participate in trials. 
 
INTRODUCTION  
 Kidney transplantation is one of the most common transplant procedures that occur each 
year in the United States. It is one of the few solutions to end-stage renal disease, which is 
mainly caused by diabetes and high blood pressure (NIH 2006). The transplantation procedure 
involves many drugs; some of the most important of these are involved in immunosuppressant 
regimes to avoid organ rejection. These drugs offer a possibility for the introduction of 
personalized medicine, or treatment based on a patient’s genetic code, to the transplantation 
process.   
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The need for immunosuppressive drugs in kidney transplantation is based in the body’s 
recognition of foreign cells as a threat to the immune system. This is largely due to human 
leukocyte antigens (HLAs) within the immune system that are specific to each person and help to 
eliminate pathogens that enter the body. Transplantation across HLA barriers without 
immunosuppressive regimes can also lead to rejection of a foreign organ. Suppression of the 
immune system is therefore important for overall graft survival in kidney transplantation.    
The drugs involved in this suppression of the immune system offer a possible application 
of pharmacogenetics to the kidney transplantation process. Through knowledge of a patient’s 
genetic code, doctors are able to create a specific dosage regimen for each person. Two drugs 
that are of special interest in this area are Tacrolimus and Cyclosporine A, which are the most 
commonly prescribed immunosuppressant drugs currently available. Both are calcineurin 
inhibitors: they inhibit the protein phosphatase that activates T cells, lymphocytes that play a role 
in cell-mediated immunity, in the immune system (Coto 2011). Tacrolimus, or Tac, suppresses 
the immune system by preventing the transcription of several cytokine genes involved in 
immune responses, thereby repressing the activation, proliferation and differentiation of T cells 
(Zhao 2009). Cyclosporine A, or CsA, is structurally distinct from Tac and binds to a different 
cytoplasmic receptor, cyclophilin A (Webster 2009). While Tac is associated with a greater risk 
of developing post-transplant diabetes, it is also associated with a decrease in graft loss when 
compared to CsA. Tac is also related to a more favorable cardiovascular risk profile, a reduced 
lipid profile and lower arterial blood pressure, and is therefore the more commonly prescribed 
immunosuppressant drug between the two (Webster 2009). 
Studies have shown that Tacrolimus is associated with a number of genes involved in 
drug metabolism. In terms of pharmacogenetics, however, it appears that currently the most 
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important of these is the CYP3A5 enzyme. This is the major enzyme involved in the metabolism 
of Tac and therefore has a large impact on the bioavailability of the drug (Coto 2011). The wild-
type allele for this gene (CYP3A5*1) leads to a functioning protein product, meaning that Tac 
will be quickly metabolized. However, there is a single nucleotide polymorphism (SNP) that has 
been found to greatly impact the overall metabolism of Tac. This SNP is CYP3A5*3, which 
affects splicing of the pre-mRNA allele, leading to poor metabolizing phenotype and absence of 
protein activity (Coto 2011). Both the CYP3A4 and the ABCB1 genes were also involved in the 
metabolism of Tac, but neither showed a large amount of pharmacogenetic variability and 
therefore is not as likely of a candidate for future research. Further studies are necessary to better 
implement pharmacogenetics in kidney transplantation (Elens 2012).  
The purpose of this research was to find a possible method to increase the number of 
participants in such a study. In order to find genes of interest and therefore specify dosage for 
immunosuppressant drugs, DNA must first be obtained from a patient. This is usually done 
through a blood sample, which requires a more invasive procedure and a trained professional for 
analysis. Both of these elements decrease the likelihood that a patient would want to participate 
in a trial, as well as complicate the process of applying personalized medicine to his treatment 
plan. Saliva samples are a possible alternative to blood samples, if sufficient DNA can be 
obtained for testing. The overall goal of this research was to begin looking into the possibility of 
less invasive methods to obtain DNA from kidney transplant recipients for the eventual 
application of pharmacogenetics in their immunosuppression regimens. In this study, it was 
hypothesized that saliva samples could produce an adequate amount and quality of DNA to be 
used in pharmacogenetic trials.  
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METHODS  
 Prior to the determination of quantity and quality of DNA obtained from saliva samples, 
the DNA had to be obtained and purified. Samples of saliva (2 mL) were taken from four 
subjects using a DNA Genotek Kit. They were mixed with stabilizing liquid and shaken, then 
stored at room temperature for one day. The samples were then incubated in an air incubator at 
50ᵒ C for 2.5 hours to ensure that the DNA was released and that the nucleases were permanently 
inactivated.  The DNA was then purified using two methods, a Genotek and a QIAgen kit, to 
determine the efficacy of both. 
Genotek Purification 
A portion of each sample (500 µL) was transferred to a microcentrifuge tube. PT-L2P (20 
µL), a reagent used for extraction of DNA, was added and the samples were vortexed. The 
samples were incubated on ice, and then centrifuged at 12,800 rpm. The supernatant was 
collected from the samples and transferred to a new microcentrifuge tube. To this, 95% ethanol 
(600 µL) was added at room temperature, and then the solutions were mixed gently by inversion 
and allowed to stand until the DNA fully precipitated. They were then centrifuged at room 
temperature. 
To the DNA pellet, 70% ethanol (250 µL) was added and allowed to stand. The ethanol 
was then removed without disturbing the pellet; complete removal was necessary so as not to 
disrupt the downstream assay. TE solution (100 µL) was added to the samples to dissolve the 
pellet, and each sample was vortexed. 
QIAgen Purification 
 Saliva from each sample (50 µL) was mixed with Buffer ATL and proteinase K, then 
pulse-vortexed and incubated at 56° C. The samples were briefly centrifuged before ethanol (50 
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µL) was added, and then the solution was vortexed and incubated at room temperature. The 
lysate was then transferred to a QIAamp MinElute column and centrifuged again. Buffer AW1 
was added (500 µL) and the solution was centrifuged again. The same process was repeated with 
Buffer AW2. Ethanol (700 µL) was then added and the solution was centrifuged, and then 
centrifuged again at full speed to dry the membrane of the column completely. The column was 
then incubated at room temperature before distilled water was applied to the center of the 
membrane, following which it was again incubated at room temperature and centrifuged at full 
speed.   
Gel Electrophoresis 
To quantify the amount of DNA, samples were then run using agarose gel 
electrophoresis: 250 mL of 0.8% TAE gel was used. A portion of each previously prepared DNA 
sample (1.2 µL) was mixed with bromophenol blue dye (4 µL) and loading buffer (5 µL) and 
injected into the wells along the negative end. A 1 kb ladder was injected into the wells on either 
end of the gel for sizing and quantification purposes. Once injected, the DNA was allowed to run 
for 45 minutes. The DNA was visualized through staining of the gel with ethidium bromide. 
After it was stained, the DNA was viewed under an ultraviolet transilluminator.  
Nanodrop Analysis  
 The concentrations of DNA were quantified using a Nanodrop spectrophotometer. The 
spectrophotometer was zeroed with water, and then a small amount of sample (2 µL) was placed 
on the pedestal. Data was obtained for each sample, and the pedestal was wiped clean between 
each trial. 
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Picogreen Analysis 
A Picogreen assay was also preformed to determine more exact values for the 
concentrations of DNA. This was done using a Picogreen spectrophotometer, with a small 
amount of sample (2 µL) mixed with a fluorescent nucleic acid stain. The values were compared 
with standard values for DNA concentrations to determine concentration.  
Polymerase Chain Reaction (PCR) and Primer 
 The DNA from both methods of purification was run with a human primer for the SNP 
RS7767396. The PCR was set up by adding to each sample HotMaster Buffer (1 µL), 2 mM 
dNTPs (1 µL), 10 µM forward primer (0.25 µL), 10 µM reverse primer (0.25 µL), HotMaster 
Taq DNA polymerase (0.25 µL) and water (6.75 µL). The thermal cycling conditions for the 
reaction were a start of 94° C (2 minutes), then 35 cycles of 94°C (20 seconds), 62° C(10 
seconds), and 65° C (30 seconds). The resulting product was run in a 1.5% TAE gel for 
electrophoresis.  
 
RESULTS  
Electrophoresis 
Gel electrophoresis was used as a primary method to determine if the purified samples 
contained DNA, as well as to determine if there was variation between the amounts obtained 
from the different purification methods. The results from the gel electrophoresis (Figure 1) 
showed that DNA was obtained from each of the saliva samples, though the amount obtained 
from each sample varied. Comparison with the 1 kb ladder showed that there were many 
different sizes of DNA fragments, and the different bands visualized in the UV light showed that 
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the samples purified with Genotek contained a larger amount of DNA than those purified 
through QIAgen. 
 
Figure 1. Image generated from the agarose gel electrophoresis, done in 0.8% TAE gel. The 
exposure was 0.288 seconds with gamma = 0 x 5, a low of 0 and a high of 1351. G denotes 
Genotek samples, and Q denotes QIAgen samples. The Genotek samples show a greater amount 
of DNA than those purified by QIAgen., with the most DNA in G3 and G4.  
Nanodrop Analysis 
A nanodrop spectrophotometer was used to obtain both the concentration of DNA and the 
purity of each sample. The results from the Nanodrop showed variation in the amount of DNA 
obtained from each sample. It was found that Genotek samples had a higher average 
concentration of DNA than QIAgen, with values of 85.375 ng/µL and 43.375 ng/µL respectively 
(Tables 1 and 2). The A260/280 ratio from the Nanodrop for each sample is indicative of protein 
contamination, as aromatic proteins have a strong UV absorbance at 280 nm. The majority of 
QIAgen samples had values over 1.8, which indicates a high level of purity (Table 1). The 
majority of values obtained for Genotek-purified samples were lower than 1.8, indicating that the 
samples were protein-contaminated (Table 2). The A260/230 ratio was indicative of organic 
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impurities, and again the values were below 1.8 indicating a large amount of impurities (Tables 1 
and 2). 
  Amount of DNA (ng/µL) A260/280 Ratio  A260/230 Ratio 
Sample 1 (QIAgen) 49 1.92 0.31 
Sample 2 (QIAgen) 72.1 2.01 0.46 
Sample 3 (QIAgen) 23.4 2.03 0.17 
Sample 4 (QIAgen) 29 1.19 0.2 
Average  43.375 1.7875 0.285 
  
   Average Without Outlier  
 
1.99 
 Table 1. Values for concentration and purity of QIAgen purified samples, determined through 
Nanodrop analysis. Averages calculated for the A260/280 both with the outlier (Sample 4) 
values and without the outlier. As a value of 1.8 indicated high purity, QIAgen samples 1 – 3 are 
above this with an average of 1.99.   
 
Amount of DNA (ng/µL) A260/280 Ratio  A260/230 Ratio 
Sample 1 (Genotek) 72.5 1.71 0.75 
Sample 2 (Genotek) 140 1.81 1.59 
Sample 3 (Genotek) 85.2 1.73 0.98 
Sample 4 (Genotek) 43.8 1.7 0.87 
Average (Genotek)  85.375 1.7375 1.0475 
Table 2. Values for concentration and purity of Genotek purified samples, determined through 
Nanodrop analysis. Purity is lower than that of QIAgen, with an average A260/280 of 1.7375 
which is lower than the desired minimum of 1.8 and indicated high protein contamination. The 
average amount obtained, however, is higher than QIAgen, with an average of 85.375 ng/µL 
compared to 43.375 ng/µL (Table 1).  
Picogreen Assay 
 Another method used to obtain the concentration of DNA in each purified sample was a 
Picogreen assay, which involves fluorescence enhancement of the DNA and comparison with 
standard concentrations. The calibration of the standards is shown in Figure 2. The data from the 
Picogreen assay also shows that Genotek-purified samples produced a larger amount of DNA 
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than QIAgen, with average amounts of 35.62 ng/µL and 10.37 ng/µL respectively. These values 
for DNA concentration are considered more accurate than those of the Nanodrop. 
 
Figure 2. Analysis of the standard DNA concentrations used in the Picogreen assay, with an R
2
 
value of 0.99507. This indicates that the standards were very close to desired concentrations, 
which validates the concentrations of DNA from the samples.   
  
Concentration of 
Experimental DNA 
(ng/µL) 
Sample 1 (QIAgen) 11.19 
Sample 2 (QIAgen) 17.73 
Sample 3 (QIAgen) 5.84 
Sample 4 (QIAgen) 6.71 
Average  10.37 
Table 3. Concentrations of DNA determined from the Picogreen assay for the QIAgen purified 
samples. The average is lower than that determined by the Nanodrop for QIAgen samples (Table 
1), as well as lower than the average determined by the Picogreen for Genotek samples (Table 4).  
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Concentration of 
Experimental DNA 
(ng/µL) 
Sample 1 (Genotek) 28.53 
Sample 2 (Genotek) 94.79 
Sample 3 (Genotek) 10.42 
Sample 4 (Genotek) 8.74 
Average (Genotek) 35.62 
Table 4. Concentrations of DNA determined from the Picogreen assay for the Genotek purified 
samples. The average is lower  than that determined by the Nanodrop for Genotek samples 
(Table 2), but still higher than the concentration determined by the Picogreen for QIAgen 
samples.  
  
Concentration of 
DNA (ng/µL) for 
Picogreen 
Concentration 
of DNA (ng/µL) 
Nanodrop 
A260/280 
Ratio  
Average (QIAgen) 10.37 43.38 1.99 
Average (Genotek) 35.62 85.38 1.74 
Table 5. Averages from both Picogreen and Nanodrop analyses of DNA concentrations. Average 
for QIAgen A260/280 ratio excludes outlier. Both values for the Genotek-purified concentrations 
are higher than those for the QIAgen purified samples. The A260/280 ratio for QIAgen is higher, 
indicating a higher level of purity.  
Primers  
 Each of the purified samples was run with a primer for the SNP RS7767396. This was to 
examine the quality of the purified DNA and whether or not a specific gene could be pulled from 
it using PCR. Following this, gel electrophoresis was used to visualize the results (Figure 3). 
Each of the samples produced a large amount of the desired gene. 
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Figure 3. Image generated from the agarose gel electrophoresis, done in 1.5% TAE gel. The 
exposure was 6.383 seconds with a low of 204 and a high of 4095. The desired product was 350 
base pairs long; the bright bands in the image are product, the lighter smears are primers. G 
denotes Genotek samples, and Q denotes QIAgen samples. While there is some variation in the 
amount from each sample, both methods were effective in purifying the DNA to an extent that it 
could be used to obtain a certain sequence of DNA, indicated viability in further 
pharmacogenetic testing.  
 
DISCUSSION 
These findings suggest that an adequate amount of DNA for further pharmacogenetic 
testing can be obtained and purified from saliva samples. While the Genotek kit produced a 
larger amount of DNA, the QIAgen kit produced an adequate amount with greater purity. It 
would be necessary to consider this high amount of impurities when choosing between uses of 
saliva or blood samples, as DNA taken from blood would likely be less contaminated.  
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The results from running the samples with primers (Figure 3) show that the DNA from 
saliva samples is viable for use with primers and PCR. Given this information, future 
experimentation will have to be done, such as running the DNA in a large-scale experiment with 
a set of 13 primers for genes commonly tested for in pharmacogenetics. Success of DNA from 
saliva in such circumstances would further support using saliva samples instead of blood 
samples.  
These results are especially applicable to kidney transplantation, as participants in studies 
would be more likely to participate if given the option of a saliva sample instead of having blood 
drawn. Saliva samples also add another benefit to possible future studies in that they could be 
analyzed in the lab rather than being sent out to special facilities. This could greatly expedite the 
process of determining a patient’s DNA and therefore lead to a faster application of a specific 
dosing regimen for that patient. It could also possibly lower the overall cost of studies conducted 
in this area, making it a favorable choice in comparison to blood samples.  
Further studies are necessary to determine the extent to which saliva samples can be 
implemented in terms of pharmacogenetic usage. It will be necessary to test the purified DNA 
with a set of primers specifically designed for pharmacogenetic use, such as for the genes 
involved in the metabolism of Tacrolimus and Cyclosporin A. If the DNA can be successfully 
run on a large scale with primers for the CYP3A5 gene, it is likely that they could be an effective 
tool in the personalized medicine of kidney transplantations.  
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